17 June 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx Pharmaceuticals" or the "Company")
Operations
Update
Hemogenyx Pharmaceuticals plc (LSE:
HEMO), the clinical stage biopharmaceutical
group developing treatments for cancers and viral diseases,
is pleased to provide an update on its ongoing
activities and progress.
1.
HEMO-CAR-T
Clinical Trials Progress:
· Additional Clinical Trial
Site: The Company has added an
additional prestigious US medical center to its list of clinical
trial sites. This will enhance the scope
and expedite the timeline for the implementation of clinical
trials.
· Clinical Site
Setup: The setup of clinical sites
at the University of Pennsylvania ("PENN") and the new medical
centre is underway. This multi-step process involves thorough
internal reviews by the science review committee and the internal
review board of both clinical sites, as well as budget negotiations
and logistics planning. The Company continues to work with
Prevail Infoworks, a contract
research organization ("CRO"), to manage and oversee the planning
for the clinical trials.
Expansion into Pediatric Indications:
Pediatric AML and ALL: The
Company is seeking to expand the HEMO-CAR-T indication to include
pediatric acute myeloid leukemia ("AML") and a subset of pediatric
acute lymphoblastic leukemia ("ALL") patients. An amendment to the
clinical protocol to include pediatric AML is currently under
review by third party experts. If approved, the Company will seek
to implement the clinical trials for pediatric AML at the newly
established clinical site. This area is of
particular concern, and there is an urgent need for effective
treatments for these conditions, which the Company believes
HEMO-CAR-T will be able to provide.
2.
Chimeric Bait Receptor ("CBR") Platform
The Company's CBR platform is an
advanced immunotherapy designed to reprogram or redirect innate
immune cells, such as macrophages, to prevent and combat infections
from both existing and emerging viral threats, as well as to
eliminate specific types of cancer.
Development and Testing:
· CBR
Constructs: Scientists at Hemogenyx
Pharmaceuticals are developing and testing multiple CBR constructs
to identify the best candidates for targeting rare cancers such as
epithelial ovarian carcinoma. Selected candidates will undergo
rigorous testing to advance them to investigational new drug (IND)
enabling studies.
mRNA-Based Delivery of CBR:
· Intranasal Delivery for Viral
Infections: The Company continues to
develop mRNA-based delivery of CBRs for treating airborne viral
infections via intranasal administration. Recent improvements in
the stability of mRNA-based CBRs are expected to enhance the
effectiveness of this treatment.
3.
CDX - Bispecific Antibody
IND-Enabling Studies:
· Progress: The Company is
advancing IND-enabling studies for CDX, a bispecific antibody
designed for treating relapsed and/or refractory AML, a subset of
ALL, and for conditioning in bone marrow transplants.
Dr
Vladislav Sandler, CEO & Co-Founder of Hemogenyx
Pharmaceuticals, commented: "We are excited
about the progress we are making across our various programs. The
addition of a world-renowned medical center to our HEMO-CAR-T
clinical trial sites marks a significant step forward in our
mission to develop life-saving therapies. Our expansion into
pediatric indications for HEMO-CAR-T highlights our commitment to
addressing unmet medical needs in both adult and pediatric
populations.
"Furthermore, our advancements in the CBR
platform and the development of mRNA-based delivery systems for
treating airborne viral infections demonstrate our innovative
approach to tackling complex diseases. The progress in our CDX
bispecific antibody program also underscores our dedication to
bringing effective treatments to patients with relapsed or
refractory AML and other severe conditions.
"We are diligently pursuing non-dilutive
financing options to support these initiatives and remain focused
on translating our scientific discoveries into clinical success. We
look forward to updating our shareholders and the market as we
continue to make strides in our development programs."
Market Abuse Regulation (MAR) Disclosure
Certain information contained in
this announcement would have been inside information for the
purposes of Article 7 of Regulation No 596/2014 (as it forms part
of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement.
Enquiries:
|
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with
its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and
Immugenyx LLC, located in New York City at its state-of-the-art
research facility.
The Company is a clinical-stage
biopharmaceutical group developing new medicines and treatments for
life-threatening diseases. Hemogenyx Pharmaceuticals is developing
several distinct and complementary product candidates, as well as a
platform technology that it uses as an engine for novel product
development.
